Nephrocare Health Services Ltd (NEPHROPLUS) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company reported a strong full-year performance for FY26, with significant growth in revenue and profitability, driven by an increase in patient volumes and treatments across its global network.
- International operations were a key growth driver, with the international mix of revenue increasing from 30% to 42%, which positively impacted the overall revenue per treatment (RPT).
- The company demonstrated improved capital efficiency, with the annual pre-tax Return on Capital Employed (ROCE) improving to 22.8% from 19.9% in the previous year, alongside better working capital management.
- Strategic expansion continued with the addition of new clinics in India and the Philippines, reinforcing its position as Asia's largest dialysis network and the world's fifth-largest by volume.
- Nephrocare is advancing its technological capabilities by implementing a proprietary AI application, Reform.AI, in 50 clinics to monitor core operations and improve clinical outcomes, with plans for a network-wide rollout.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.